These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9158779)

  • 1. Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience.
    Low DE
    Microb Drug Resist; 1995; 1(3):223-34. PubMed ID: 9158779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E; Bompart F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinupristin-dalfopristin.
    Bryson HM; Spencer CM
    Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
    Bouanchaud DH
    J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
    Ling TK; Fung KS; Cheng AF
    Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
    Tünger A; Aydemir S; Uluer S; Cilli F
    Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination.
    Griswold MW; Lomaestro BM; Briceland LL
    Am J Health Syst Pharm; 1996 Sep; 53(17):2045-53. PubMed ID: 8870891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
    Jones RN; Low DE; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinupristin/dalfopristin: a therapeutic review.
    Allington DR; Rivey MP
    Clin Ther; 2001 Jan; 23(1):24-44. PubMed ID: 11219478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
    Wang FD; Lin ML; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections.
    Manzella JP
    Am Fam Physician; 2001 Dec; 64(11):1863-6. PubMed ID: 11764864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antibiotics for infections caused by resistant organisms.
    McKinnon PS; Tam VH
    Support Care Cancer; 2001 Jan; 9(1):8-10. PubMed ID: 11147147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.
    Klastersky J
    Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
    Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.